Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bevenopran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14159395 | 0.92 | MAPK1 (0.42) | MAPK1LMNAKDM4EPOLBCYP3A4 | |
| SCHEMBL12836114 | 0.91 | LMNA (0.42) | MAPK1LMNAKDM4EPOLBCYP3A4 | |
| SCHEMBL3691965 | 0.90 | OPRM1 (0.41) | MAPK1LMNAOPRM1OPRD1OPRK1 | |
| SCHEMBL3692183 | 0.89 | OPRM1 (0.41) | OPRM1OPRD1OPRK1MCHR1CTSD | |
| SCHEMBL3888284 | 0.88 | OPRM1 (0.46) | MAPK1LMNAOPRM1OPRD1OPRK1 | |
| SCHEMBL3695565 | 0.88 | OPRM1 (0.46) | MAPK1LMNAOPRM1OPRD1OPRK1 | |
| SCHEMBL3690720 | 0.87 | OPRM1 (0.41) | MAPK1LMNAOPRM1OPRD1OPRK1 | |
| SCHEMBL3690745 | 0.85 | OPRM1 (0.44) | MAPK1LMNAOPRM1OPRD1OPRK1 | |
| SCHEMBL3691865 | 0.85 | OPRM1 (0.44) | MAPK1LMNAOPRM1OPRD1OPRK1 | |
| SCHEMBL3705019 | 0.85 | OPRM1 (0.47) | OPRM1OPRD1OPRK1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137697-A1 | METHODS, SYSTEMS, AND COMPOSITIONS RELATED TO USE OF MU OPIOID RECEPTOR (MOR) ANTAGONISTS | GLYCYX MOR INC. (US) | 2025-06-26 | — | — | WO | claimed |
| US-20240209403-A1 | METHODS OF PRODUCING MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-06-27 | — | — | US | claimed |
| US-11884949-B2 | Methods of producing morphinan alkaloids and derivatives | ANTHEIA, INC. (US) | 2024-01-30 | — | — | US | claimed |
| US-20230407258-A1 | TREATMENT OF DISC DEGENERATIVE DISEASE AND STIMULATION OF PROTEOGLYCAN SYNTHESIS BY FIBROBLAST CONDITIONED MEDIA AND FORMULATIONS THEREOF | FIGENE, LLC | 2023-12-21 | — | — | US | claimed |
| EP-4031167-A1 | TREATMENT OF DISC DEGENERATIVE DISEASE AND STIMULATION OF PROTEOGLYCAN SYNTHESIS BY FIBROBLAST CONDITIONED MEDIA AND FORMULATIONS THEREOF | Figene, LLC (US) | 2022-07-27 | — | — | EP | claimed |
| US-20220125844-A1 | OPIOID ANTAGONISTS FOR USE IN PATIENTS USING CHIMERIC ANTIGEN RECEPTOR T AND NATURAL KILLER (NK) CELL THERAPY | THE JOHNS HOPKINS UNIVERSITY | 2022-04-28 | — | — | US | claimed |
| EP-2208727-B1 | Diaryl ethers as opioid receptor antagonist | LILLY CO ELI (US) | 2012-08-29 | — | — | EP | claimed |
| JP-4646628-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| EP-2208727-A1 | Diaryl ethers as opioid receptor antagonist | Eli Lilly & Company (US) | 2010-07-21 | — | — | EP | claimed |
| US-7560463-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-07-14 | — | — | US | claimed |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | claimed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | claimed |
| EP-1562595-B1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-05-21 | — | — | EP | claimed |
| CN-1305852-C | Diaryl ethers as opioid receptor antagonists | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | claimed |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | claimed |
| JP-2006511474-A | — | — | 2006-04-06 | — | — | JP | claimed |
| CN-1681498-A | Diaryl ethers as opioid receptor antagonist | LILLY CO ELI (US) | 2005-10-12 | — | — | CN | claimed |
| EP-1562595-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | claimed |
| EP-4739375-A1 | HIGHLY PORTABLE GAS DELIVERY SYSTEMS | Minogue, Michael R. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12611418-B2 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2026-04-28 | — | — | US | disclosed |
| US-20260103736-A1 | Methods Of Improving Production Of Morphinan Alkaloids And Derivatives | ANTHEIA INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3946547-B1 | DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS | PINOVA THERAPEUTICS INC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4704806-A1 | INJECTABLE PHARMACEUTICAL FORMULATIONS | Cybin IRL Limited (IE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4673140-A1 | METHODS OF TREATING DEPRESSIVE DISORDERS WITH A PSILOCYBIN ANALOG | Cybin IRL Limited (IE) | 2026-01-07 | — | — | EP | disclosed |
| US-20250367223-A1 | METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | COMPASS PATHFINDER LIMITED (GB) | 2025-12-04 | — | — | US | disclosed |
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | CYBIN IRL LIMITED (IE) | 2025-11-27 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-12447164-B2 | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2025-10-21 | — | — | US | disclosed |
| US-20250312275-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | NANEXA AB (SE) | 2025-10-09 | — | — | US | disclosed |
| US-12433904-B2 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2025-10-07 | — | — | US | disclosed |
| EP-4594342-A2 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | Antheia, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250236589-A1 | THERAPEUTIC PHENETHYLAMINE COMPOSITIONS AND METHODS OF USE | CYBIN IRL LIMITED (IE) | 2025-07-24 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250213527-A1 | FORMULATIONS OF PSILOCYBIN ANALOGS AND METHODS OF USE | CYBIN IRL LIMITED (IE) | 2025-07-03 | — | — | US | disclosed |
| WO-2025137697-A1 | METHODS, SYSTEMS, AND COMPOSITIONS RELATED TO USE OF MU OPIOID RECEPTOR (MOR) ANTAGONISTS | GLYCYX MOR INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025106940-A1 | HIGHLY PORTABLE GAS DELIVERY SYSTEMS | MINOGUE MICHAEL R (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250152889-A1 | HIGHLY PORTABLE GAS DELIVERY SYSTEMS | MINOGUE, MICHAEL | 2025-05-15 | — | — | US | disclosed |
| US-20250145566-A1 | PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | CYBIN IRL LIMITED (IE) | 2025-05-08 | — | — | US | disclosed |
| US-20250137021-A1 | METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2025-05-01 | — | — | US | disclosed |
| EP-4536179-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | Nanexa AB (SE) | 2025-04-16 | — | — | EP | disclosed |
| US-20250082607-A2 | METHODS OF TREATING DISORDERS WITH A PSILOCYBIN ANALOG | CYBIN IRL LIMITED (IE) | 2025-03-13 | — | — | US | disclosed |
| US-20250058094-A1 | DEVICES AND METHODS FOR DELIVERY OF PHARMACEUTICAL COMPOSITIONS | PINOVA THERAPEUTICS INC. | 2025-02-20 | — | — | US | disclosed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | disclosed |
| US-12194263-B2 | Devices and methods for delivery of pharmaceutical compositions | Pocket Naloxone Corp. (US) | 2025-01-14 | — | — | US | disclosed |
| US-12180525-B2 | Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| WO-2024256696-A1 | NEW INJECTABLE PHARMACEUTICAL DEPOT COMPOSITIONS | NANEXA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| US-20240404619-A1 | Machine Learning and Molecular Simulation Based Methods for Enhancing Binding and Activity Prediction | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4463440-A1 | TRYPTAMINE COMPOSITIONS AND METHODS | Cybin IRL Limited (IE) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024231331-A1 | INJECTABLE PHARMACEUTICAL FORMULATIONS | CYBIN IRL LIMITED (IE) | 2024-11-14 | — | — | WO | disclosed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | disclosed |
| US-12100485-B2 | Machine learning and molecular simulation based methods for enhancing binding and activity prediction | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-09-24 | — | — | US | disclosed |
| US-12090276-B1 | Highly portable gas delivery systems | Minogue, Michael R. (US) | 2024-09-17 | — | — | US | disclosed |
| EP-4426675-A1 | FORMULATIONS OF PSILOCYBIN ANALOGS AND METHODS OF USE | Cybin IRL Limited (IE) | 2024-09-11 | — | — | EP | disclosed |
| CN-118632835-A | Tryptamine compositions and methods | 赛本爱尔兰有限公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2024180030-A1 | METHODS OF TREATING DEPRESSIVE DISORDERS WITH A PSILOCYBIN ANALOG | CYBIN IRL LIMITED (IE) | 2024-09-06 | — | — | WO | disclosed |
| US-20240293367-A1 | METHODS OF TREATING DISORDERS WITH A PSILOCYBIN ANALOG | CYBIN IRL LIMITED (IE) | 2024-09-05 | — | — | US | disclosed |
| US-20240261228-A1 | NEW PROCESS | NANEXA AB (SE) | 2024-08-08 | — | — | US | disclosed |
| US-20240252521-A1 | METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | COMPASS PATHFINDER LIMITED (GB) | 2024-08-01 | — | — | US | disclosed |
| US-20240209403-A1 | METHODS OF PRODUCING MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-06-27 | — | — | US | disclosed |
| CN-118234708-A | Formulations of nudity alkali analogs and methods of use | 赛本爱尔兰有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024127018-A1 | NEW INJECTABLE SUSPENSION OF COATED PARTICLES | NANEXA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| US-12006329-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240165103-A1 | COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY | PURDUE PHARMA LP (US) | 2024-05-23 | — | — | US | disclosed |
| CN-112204402-B | Methods for enhancing binding and activity prediction based on machine learning and molecular modeling | 斯坦福大学托管董事会 | 2024-05-03 | — | — | CN | disclosed |
| EP-4351528-A1 | NEW PROCESS | Nanexa AB (SE) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024073755-A2 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | ANTHEIA, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240102061-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-03-28 | — | — | US | disclosed |
| US-11884949-B2 | Methods of producing morphinan alkaloids and derivatives | ANTHEIA, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11865126-B2 | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-11865112-B2 | Compositions and methods for opioid antagonist delivery | PURDUE PHARMA L.P. (US) | 2024-01-09 | — | — | US | disclosed |
| US-11857547-B2 | Compositions and methods for opioid antagonist delivery | PURDUE PHARMA L.P. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023247665-A1 | SOLID DISPERSIONS OF PSILOCYBIN | CYBIN IRL LIMITED (IE) | 2023-12-28 | — | — | WO | disclosed |
| US-20230407258-A1 | TREATMENT OF DISC DEGENERATIVE DISEASE AND STIMULATION OF PROTEOGLYCAN SYNTHESIS BY FIBROBLAST CONDITIONED MEDIA AND FORMULATIONS THEREOF | FIGENE, LLC | 2023-12-21 | — | — | US | disclosed |
| WO-2023237897-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | NANEXA AB (SE) | 2023-12-14 | — | — | WO | disclosed |
| CN-116964190-A | Method for increasing yields of morphinan alkaloids and derivatives | 安思雅公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230330117-A1 | METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | COMPASS PATHFINDER LIMITED (GB) | 2023-10-19 | — | — | US | disclosed |
| EP-4247937-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | Antheia, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230270741-A1 | COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY | PURDUE PHARMA LP (US) | 2023-08-31 | — | — | US | disclosed |
| US-11738035-B2 | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2023-08-29 | — | — | US | disclosed |
| US-20230265153-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD (GB) | 2023-08-24 | — | — | US | disclosed |
| US-11732239-B2 | Treatment of disc degenerative disease and stimulation of proteoglycan synthesis by fibroblast conditioned media and formulations thereof | FIGENE, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2023135237-A1 | TRYPTAMINE COMPOSITIONS AND METHODS | CYBIN IRL LIMITED (IE) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022109194-A9 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | ANTHEIA, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230157968-A1 | INJECTABLE OIL-BASED PHARMACEUTICAL COMPOSITION | NANEXA AB (SE) | 2023-05-25 | — | — | US | disclosed |
| WO-2023078604-A1 | FORMULATIONS OF PSILOCYBIN ANALOGS AND METHODS OF USE | CYBIN IRL LIMITED (IE) | 2023-05-11 | — | — | WO | disclosed |
| CN-116075295-A | Novel injectable oil-based pharmaceutical compositions | 南爱克萨股份公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20230126298-A1 | DEUYERATED TRYPTAMINE DERIVATIVE FORMULATIONS AND METHODS OF USE | CYBIN IRL LIMITED (IE) | 2023-04-27 | — | — | US | disclosed |
| US-20230124137-A1 | METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | COMPASS PATHFINDER LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-11623932-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20230104286-A1 | METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2023-04-06 | — | — | US | disclosed |
| EP-4135672-A1 | INJECTABLE OIL-BASED PHARMACEUTICAL COMPOSITION | Nanexa AB (SE) | 2023-02-22 | — | — | EP | disclosed |
| US-11564935-B2 | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2023-01-31 | — | — | US | disclosed |
| US-20230020272-A1 | NEW PROCESS FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS | NANEXA AB (SE) | 2023-01-19 | — | — | US | disclosed |
| US-20230009472-A1 | NEW COMPOSITION | NANEXA AB (SE) | 2023-01-12 | — | — | US | disclosed |
| US-11548928-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2023-01-10 | — | — | US | disclosed |
| US-20230000883-A1 | METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | HERCULES CAPITAL, INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2022258984-A1 | NEW PROCESS | NANEXA AB (SE) | 2022-12-15 | — | — | WO | disclosed |
| US-11518796-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2022-12-06 | — | — | US | disclosed |
| EP-4069198-A1 | NEW PROCESS FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS | Nanexa AB (SE) | 2022-10-12 | — | — | EP | disclosed |
| EP-4069190-A1 | NEW COMPOSITION | Nanexa AB (SE) | 2022-10-12 | — | — | EP | disclosed |
| US-20220307132-A1 | APPARATUS | NANEXA AB (SE) | 2022-09-29 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-115087665-A | Engineered platelets for targeted delivery of therapeutic agents | JPV01有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-11427827-B2 | Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220251165-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-08-11 | — | — | US | disclosed |
| EP-4031167-A1 | TREATMENT OF DISC DEGENERATIVE DISEASE AND STIMULATION OF PROTEOGLYCAN SYNTHESIS BY FIBROBLAST CONDITIONED MEDIA AND FORMULATIONS THEREOF | Figene, LLC (US) | 2022-07-27 | — | — | EP | disclosed |
| US-11396668-B2 | Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| EP-4026898-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-07-13 | — | — | EP | disclosed |
| CN-114746078-A | New composition | 南爱克萨股份公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2022109194-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | ANTHEIA, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220162656-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2022-05-26 | — | — | US | disclosed |
| EP-3990679-A1 | APPARATUS FOR FORMING A PLURALITY OF COATED PARTICLES, METHOD FOR FORMING A PLURALITY OF COATED PARTICLES, COATED PARTICLES | Nanexa AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| US-20220125844-A1 | OPIOID ANTAGONISTS FOR USE IN PATIENTS USING CHIMERIC ANTIGEN RECEPTOR T AND NATURAL KILLER (NK) CELL THERAPY | THE JOHNS HOPKINS UNIVERSITY | 2022-04-28 | — | — | US | disclosed |
| US-20220088041-A1 | METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | COMPASS PATHFINDER LIMITED (GB) | 2022-03-24 | — | — | US | disclosed |
| US-20220071991-A1 | EXTENDED RELEASE COMPOSITIONS OF OPIOID ANTAGONISTS AND PHOSPHODIESTERASE 5 INHIBITORS | PARDON MY SCOTCH LLC (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220062602-A1 | DEVICES AND METHODS FOR DELIVERY OF PHARMACEUTICAL COMPOSITIONS | PINOVA THERAPEUTICS INC. | 2022-03-03 | — | — | US | disclosed |
| EP-3955919-A1 | METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | COMPASS Pathfinder Limited (GB) | 2022-02-23 | — | — | EP | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3946547-A1 | DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS | Pocket Naloxone Corp. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3947633-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | Antheia, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| CN-114026265-A | Apparatus for forming a plurality of coated particles, method for forming a plurality of coated particles, coated particles | 南爱克萨股份公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-113993522-A | Method for treating anxiety disorders, headache disorders and eating disorders with siloxibin | 指南针探路者有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-104958298-A | Use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders | ADOLOR CORP | 2015-10-07 | — | — | CN | disclosed |
| CN-102695508-A | Use of opioid receptor antagonists for gastrointestinal disorders | ADOLOR CORP | 2012-09-26 | — | — | CN | disclosed |
| EP-2208727-B1 | Diaryl ethers as opioid receptor antagonist | LILLY CO ELI (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2477627-A1 | USE OF OPIOID RECEPTOR ANTAGONIST FOR GASTROINTESTINAL TRACT DISORDERS | Adolor Corporation (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-2477627-A1 | USE OF OPIOID RECEPTOR ANTAGONIST FOR GASTROINTESTINAL TRACT DISORDERS | Adolor Corporation (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011035142-A1 | USE OF OPIOID RECEPTOR ANTAGONIST FOR GASTROINTESTINAL TRACT DISORDERS | ADOLOR CORPORATION (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011035142-A1 | USE OF OPIOID RECEPTOR ANTAGONIST FOR GASTROINTESTINAL TRACT DISORDERS | ADOLOR CORPORATION (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011035142-A1 | USE OF OPIOID RECEPTOR ANTAGONIST FOR GASTROINTESTINAL TRACT DISORDERS | ADOLOR CORPORATION (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110071163-A1 | USE OF AN OPIOID RECEPTOR ANTAGONIST FOR THE TREATMENT OR PREVENTION OF GASTROINTESTINAL TRACT DISORDERS | ADOLOR CORPORATION (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071163-A1 | USE OF AN OPIOID RECEPTOR ANTAGONIST FOR THE TREATMENT OR PREVENTION OF GASTROINTESTINAL TRACT DISORDERS | ADOLOR CORPORATION (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071163-A1 | USE OF AN OPIOID RECEPTOR ANTAGONIST FOR THE TREATMENT OR PREVENTION OF GASTROINTESTINAL TRACT DISORDERS | ADOLOR CORPORATION (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071163-A1 | USE OF AN OPIOID RECEPTOR ANTAGONIST FOR THE TREATMENT OR PREVENTION OF GASTROINTESTINAL TRACT DISORDERS | ADOLOR CORPORATION (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2208727-A1 | Diaryl ethers as opioid receptor antagonist | Eli Lilly & Company (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-2208727-A1 | Diaryl ethers as opioid receptor antagonist | Eli Lilly & Company (US) | 2010-07-21 | — | — | EP | disclosed |
| US-7560463-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560463-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560463-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560463-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-07-14 | — | — | US | disclosed |
| US-7531557-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531557-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531557-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | BLANCO-PILLADO MARIA-JESUS | 2008-10-30 | — | — | US | disclosed |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | BLANCO-PILLADO MARIA-JESUS | 2008-10-30 | — | — | US | disclosed |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | BLANCO-PILLADO MARIA-JESUS | 2008-10-30 | — | — | US | disclosed |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1562595-B1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1562595-B1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| EP-1562595-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004026305-A9 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | LILLY CO ELI (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082607-A2 | METHODS OF TREATING DISORDERS WITH A PSILOCYBIN ANALOG | HTR2C, HTR1B, HTR2A | OPRM1 16/4885MAPK1 4726/4885LMNA 286/4885 |
| US-20250236589-A1 | THERAPEUTIC PHENETHYLAMINE COMPOSITIONS AND METHODS OF USE | PNMT, HTR2C, HTR2A | OPRM1 40/4885MAPK1 4459/4885LMNA 2310/4885 |
| US-12006329-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | OPRM1 4693/4885MAPK1 3746/4885LMNA 2563/4885 |
| US-20250213527-A1 | FORMULATIONS OF PSILOCYBIN ANALOGS AND METHODS OF USE | HTR2C, HTR2A, HTR2B | OPRM1 21/4885MAPK1 4757/4885LMNA 2239/4885 |
| US-20260103736-A1 | Methods Of Improving Production Of Morphinan Alkaloids And Derivatives | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885MAPK1 4009/4885LMNA 3778/4885 |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRL1 | OPRM1 1/4885MAPK1 2452/4885LMNA 4007/4885 |
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | HTR2B, HTR2A, HTR2C | OPRM1 181/4885MAPK1 4622/4885LMNA 3478/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | OPRM1 4693/4885MAPK1 3746/4885LMNA 2563/4885 |
| US-12611418-B2 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | HTR1D, HTR1B, HTR2B | OPRM1 114/4885MAPK1 3396/4885LMNA 534/4885 |
| US-11623932-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | OPRM1 4693/4885MAPK1 3746/4885LMNA 2563/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | OPRM1 4693/4885MAPK1 3746/4885LMNA 2563/4885 |
| US-20110071163-A1 | USE OF AN OPIOID RECEPTOR ANTAGONIST FOR THE TREATMENT OR PREVENTION OF GASTROINTESTINAL TRACT DISORDERS | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885MAPK1 640/4885LMNA 4639/4885 |
| US-20240293367-A1 | METHODS OF TREATING DISORDERS WITH A PSILOCYBIN ANALOG | HTR2C, HTR1B, HTR2A | OPRM1 16/4885MAPK1 4726/4885LMNA 286/4885 |
| US-20230126298-A1 | DEUYERATED TRYPTAMINE DERIVATIVE FORMULATIONS AND METHODS OF USE | TPH2, HTR2A, HTR2C | OPRM1 197/4885MAPK1 4798/4885LMNA 1766/4885 |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRL1 | OPRM1 1/4885MAPK1 2410/4885LMNA 3993/4885 |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | OPRM1, OPRL1, OPRD1 | OPRM1 1/4885MAPK1 2437/4885LMNA 3897/4885 |
| US-20250145566-A1 | PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | PNMT, HTR7, HTR2C | OPRM1 31/4885MAPK1 2955/4885LMNA 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.